Alveolar Rhabdomyosarcoma Treatment Market Therapeutics 2020: Top Company Profiles Global Size, Global Opportunity, Demand and Competitive Share Analysis Till 2026

SEATTLE, March 25, 2021, (PHARMIWEB) — Global Alveolar Rhabdomyosarcoma (ARMS) Treatment Market

Alveolar Rhabdomyosarcoma (ARMS) is a type of soft tissue sarcoma that originates from the connective tissues of the body such as bone, muscle, cartilage, and ligaments. According to the survey conducted by the Children’s Oncology Group, 2011, alveolar rhabdomyosarcoma makes up about 25-40% of RMS. ARMS is mostly detected in adolescents and often occurs on the arms, legs, chest, and stomach. The exact cause of alveolar rhabdomyosarcoma is unknown; however, it is associated with other conditions, such as Neurofibromatosis type 1, Beckwith-Wiedemann syndrome, Li-Fraumeni syndrome, Cardio-facio-cutaneous syndrome, and Costello syndrome. The methods for diagnosis of ARMS include examination such as X-ray imaging, CT scan, MRI, bone scan, ultrasound, PET scan, and a biopsy, in order to plan a suitable treatment for the condition. ARMS is a type of high-grade tumor, which is characterized by the rapid growth and faster progression of cells.

To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/1552

According to the Surveillance, Epidemiology, and End Results (SEER) database, ARMS constitutes 23% of patients among the types of RMS. Also, alveolar rhabdomyosarcoma needs more-intensive therapy than embryonal rhabdomyosarcoma. Radiation therapy including intensity-modulated radiotherapy (IMRT) and proton beam radiation therapy are implemented as an effective way to shrink the tumor cells post chemotherapy. Mostly, chemotherapy and radiation therapy is used to shrink the size of the tumor before surgery and to minimize the risk of cancer reoccurrence post-surgery.

Global ARMS Treatment Market Insights

Rising incidence of alveolar rhabdomyosarcoma along with technological advancements in radiation therapy is expected to augment market growth of alveolar rhabdomyosarcoma treatment. According to the survey by the University of Minnesota, 2014, soft tissue sarcomas (STS) comprises about 7% of all malignancies in children and adolescents under the age of 20 years and rhabdomyosarcoma (RMS) accounts for about 40% of pediatric STS. The incidence of RMS is 4.5 cases/million children/adolescents per year, where ARMS accounts for 31% of RMS, and in 50% cases the condition is highly prevalent below the age of 10. Also, latest advancements in radiation therapy, which are largely adopted by major hospitals such as Mayo Clinic, Memorial Sloan Kettering Cancer Center include proton beam therapy program that provides highly targeted precision beams to destroy cancerous cells by sparing the healthy surrounding tissues.

Exclusive offer!!! Purchase the report at a discounted rate!!!

Apply Promo Code “CMIFIRST1000” and Get Up to 30% Discount

Quick Buy – Alveolar Rhabdomyosarcoma Treatment Market Research Report: https://bit.ly/3lOX4pk

Moreover, various government and non-government organizations are undertaking research initiatives to improve the outcomes of alveolar rhabdomyosarcoma, as the condition is often results in lower survival rates. Several clinical trials are conducted by large international cooperative groups, such as Soft Tissue Sarcoma Committee of the Children’s Oncology Group (COG) and the National Comprehensive Cancer Network (NCCN) to provide innovative treatments based on latest research, which in turn is expected to bolster market growth in the forecast period. Also, researchers at Oregon Health & Science University Doernbecher Children’s Hospital have identified a promising new approach to overcoming drug resistance and increase the survival rate in children with alveolar rhabdomyosarcoma. According to the Oregaon Health and Science University, the survival rate among alveolar rhabdomyosarcoma patients, after extensive therapies, is less than 20%.

Several organizations and manufacturers are currently conducting clinical trials to investigate novel therapies to treat pediatric cancers. For instance, in 2015, Novartis Pharmaceuticals initiated the Phase 1 study for Trametinib in combination with Dabrafenib in children and adolescents with alveolar rhabdomyosarcoma harboring V600 mutations.

Global ARMS Treatment Market – Regional Outlook

North America is expected to hold a dominant position in the global alveolar rhabdomyosarcoma treatment market over the forecast period, owing to rising number of initiatives undertaken by organizations in the region to develop potential therapies, increasing research and development, and adoption of advanced radiation therapies. Organizations in the region have initiated the first molecular targeted drug in a clinical trial in 2011, for childhood muscle cancer at the Doernbecher Children’s Hospital and Children Oncology Group (COG) sites. Also, St. Baldrick’s Foundation works in collaboration with pediatric oncologists and funds supportive cancer research to develop promising research to positively impact treatment of children with cancer. Moreover, other organization such as the National Cancer Institute, Scott Carter Foundation, Alex’s Lemonade Stand Foundation, and the Hyundai Hope on Wheels Program have funded various studies, in order to explore highly potential therapeutic options. The alveolar rhabdomyosarcoma treatment market in Asia Pacific is expected to witness high growth, owing to rising awareness of the disease in the regions supported by advancements in the medical settings to adopt novel therapies.

*The Download PDF brochure only consist of Table of Content, Research Framework, and Research Methodology.

Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/1552

Global ARMS Treatment Market – Competitive Background

The most prominent players operating in the global alveolar rhabdomyosarcoma treatment market include Eli Lilly and Company, GlaxoSmithKline Plc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb, F. Hoffmann-La Roche AG, Oasmia Pharmaceutical, Celgene Corporation, Pfizer, Inc., and Johnson & Johnson Services, Inc.

Market Taxonomy

On the basis of therapy type:

• Chemotherapy
• Radiation Therapy
• Combination Therapy

By end-user:

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers

Table of Content

Global Alveolar Rhabdomyosarcoma Treatment Market Research Report
Section 1: Global Alveolar Rhabdomyosarcoma Treatment Industry Overview
Section 2: Global Economic Impact on Alveolar Rhabdomyosarcoma Treatment Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Alveolar Rhabdomyosarcoma Treatment Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Alveolar Rhabdomyosarcoma Treatment Market Forecast

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837